Home > Insider Trading > Filing (0000903423-18-000527)

Filing Details

Accession Number:: 0000903423-18-000527
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-10-02 16:46:58
Reporting Period:: 2018-09-28

Accepted Time:: 2018-10-02 16:46:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1724344	Entasis Therapeutics Holdings Inc.	ETTX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
860866	David Bonderman	C/O Tpg Global, Llc, 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	Yes	Yes
1099776	G James Coulter	C/O Tpg Global, Llc, 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	Yes	Yes
1495741	Tpg Group Holdings (Sbs) Advisors, Inc.	C/O Tpg Global, Llc, 301 Commerce Street, Suite 3300 Fort Worth TX 76102	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-09-28	735,924	$0.00	735,924	No	4	C	Indirect	See Explanation of Responses
Common Stock	Acquisiton	2018-09-28	22,285	$0.00	758,209	No	4	J	Indirect	See Explanation of Responses
Common Stock	Acquisiton	2018-09-28	262,539	$15.00	1,020,748	No	4	P	Indirect	See Explanation of Responses

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Explanation of Responses
No	4	J	Indirect	See Explanation of Responses
No	4	P	Indirect	See Explanation of Responses

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B-1 Preferred Stock	Disposition	2018-09-28	15,254,237	$0.00	735,924	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

David Bonderman and James G. Coulter are the sole shareholders of TPG Group Holdings (SBS) Advisors, Inc. (together with Messrs. Bonderman and Coulter, the "Reporting Persons"), which is the sole member of TPG Group Holdings (SBS) Advisors, LLC, which is the general partner of TPG Group Holdings (SBS), L.P., which is the sole member of TPG Holdings I-A, LLC, which is the general partner of TPG Holdings I, L.P., which is the sole member of TPG Biotech GenPar V Advisors, LLC, which is the general partner of TPG Biotechnology GenPar V, L.P., which is the general partner of TPG Biotech V ENT, L.P. ("TPG Biotech V"), which holds 1,020,748 shares of Common Stock, par value $0.001 per share ("Common Stock"), of Entasis Therapeutics Holdings Inc. (the "Issuer").
On September 28, 2018, the shares of Series B-1 Preferred Stock of the Issuer (the "Series B-1 Preferred") held by TPG Biotech V automatically converted into 735,924 shares of Common Stock. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B-1 Preferred had been convertible, at the option of the holder, at any time into shares Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B-1 Preferred. The initial conversion rate was adjusted as a result of a 1-for-20.728 reverse stock split of the Issuer's Common Stock.
On September 28, 2018, the Issuer paid to TPG Biotech V accrued but unpaid dividends on the Series B-1 Preferred in 22,285 shares of Common Stock.
On September 28, 2018, TPG Biotech V acquired 262,539 shares of Common Stock at a price of $15.00 per share in connection with the Issuer's initial public offering.
Because of the relationship between the Reporting Persons and TPG Biotech V, the Reporting Persons may be deemed to beneficially own the securities reported herein to the extent of the greater of their respective direct or indirect pecuniary interests in the profits or capital accounts of TPG Biotech V. TPG Biotech V and each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of TPG Biotech V's or such Reporting Person's pecuniary interest therein, if any.
Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.